The therapy of Sjogren's syndrome: a review.
The Sjogren's syndrome (SS) is an chronic inflammatory autoimmune disease of the exocrine glands as well as of internal apparatus. The therapy of exocrinopathy is represented by parasympathomimetic drugs such as pilocarpine and cevimeline. The therapy of systemic manifestations, actually is represented by the inhibitors of TNF alfa, as well as leflunomide, methotrexate and cyclosporine-A, but the results are quite insufficient and disappointed. In order to the involvement of B-cell function in the pathogenesis of SS, one of the most important option in the future should be specific inhibitors of that cells.
Coaccioli
S
S
Dept. of Internal Medicine and Rheumatology Unit, Perugia University School of Medicine, Terni, Italy. scoaccioli@tin.it
Giuliani
M
M
Puxeddu
A
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes / Q000187:drug effects; D016572:Cyclosporine / Q000627:therapeutic use; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D008727:Methotrexate / Q000627:therapeutic use; D018721:Muscarinic Agonists / Q000627:therapeutic use; D010277:Parasympathomimetics / Q000627:therapeutic use*; D010862:Pilocarpine / Q000627:therapeutic use; D011812:Quinuclidines / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013876:Thiophenes / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014985:Xerophthalmia / Q000517:prevention & control; D014987:Xerostomia / Q000517:prevention & control
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D018721:Muscarinic Agonists; D010277:Parasympathomimetics; D011812:Quinuclidines; D018124:Receptors, Tumor Necrosis Factor; D013876:Thiophenes; D014409:Tumor Necrosis Factor-alpha; D010862:Pilocarpine; C448700:epratuzumab; D000069283:Rituximab; D016572:Cyclosporine; D000069285:Infliximab; D000077339:Leflunomide; C059240:cevimeline; D000068800:Etanercept; D008727:Methotrexate